Ayesha Sultana

Ayesha Sultana

Auto-generated profile, based on publicly available information

Ayesha Sultana

Department of Pharmaceutics,Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
MHMd Sadique Hussain
Md Sadique Hussain
ASAyesha Sultana
Ayesha Sultana
ABAjay Singh Bisht
Ajay Singh Bisht
GGGaurav Gupta
Gaurav Gupta
The advent of mRNA vaccines has heralded a transformative era in oncology, exemplified by the BNT116 mRNA lung cancer vaccine. Leveraging the same groundbreaking technology as COVID-19 vaccines, BNT116 delivers tumor-specific genetic instructions to the immune system, targeting non-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype. This approach contrasts with conventional therapies that lack precision and often damage healthy tissues. By encoding tumor antigens, BNT116 educates cytotoxic T cells to recognize and eradicate malignant cells, aligning with the principles of precision medicine. Early-phase clinical trials (e.g., NCT05142189) have demonstrated a favorable safety profile and promising antitumor activity, with ongoing research exploring its use in combination therapies, such as checkpoint inhibitors. Despite logistical challenges, such as mRNA instability and cold chain requirements, advances in lipid nanoparticle delivery systems are enhancing vaccine stability and efficacy. The adaptability of mRNA technology positions it as a cornerstone for personalized oncology, with potential applications extending to other cancers. Success in the BNT116 trials could redefine NSCLC treatment paradigms, offering a targeted, less cytotoxic alternative. This innovation can not only improve therapeutic outcomes, but also pave the way for preventive cancer vaccines, signaling a new dawn in cancer treatment.

16 July 2025 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
ARAmita Joshi Rana
Amita Joshi Rana
MHMd Sadique Hussain
Md Sadique Hussain
VJVikas Jakhmola
Vikas Jakhmola
ASAyesha Sultana
Ayesha Sultana
SKSreeshma Ravindran Kammarambath
Sreeshma Ravindran Kammarambath
Dr Inamul Hasan Hasan MadarDr Inamul Hasan Hasan Madar
Dr Inamul Hasan Hasan Madar

1 November 2025 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
PDF file
MHMd Sadique Hussain
Md Sadique Hussain
VJVikas Jakhmola
Vikas Jakhmola
ASAyesha Sultana
Ayesha Sultana
ABAjay Singh Bisht
Ajay Singh Bisht
GKGyas Khan
Gyas Khan
Circular RNAs (circRNAs) have emerged as promising candidates for neoantigen vaccine development due to their unique structural stability, enhanced translational efficiency, and immunostimulatory properties. Unlike linear RNAs, circRNAs exhibit exonuclease resistance, prolonged antigen expression, and increased activation of innate immune receptors such as RIG-I and MDA5, thereby enhancing anti-tumor immune responses. Preclinical studies have demonstrated that circRNA-based vaccines encoding tumor-specific neoantigens effectively stimulate Antigen- Presenting Cells (APCs), particularly Dendritic Cells (DCs), leading to robust CD8+ Cytotoxic T Lymphocyte (CTL) activation. This results in increased cytokine production, T-cell proliferation, and durable anti-tumor immunity. Compared to conventional neoantigen vaccine platforms, circRNA vaccines offer distinct advantages, including higher immunogenicity, improved cytosolic delivery, and minimal risk of genomic integration. CircRNA vaccines have demonstrated efficacy in preclinical tumor models, with studies highlighting their ability to induce long-term memory T-- cell responses and enhance the efficacy of immune checkpoint blockade therapies. However, challenges remain in optimizing circRNA delivery, mitigating unintended immune activation, and scaling up manufacturing processes. The translational potential of circRNA vaccines in tumor immunotherapy is significant, offering a novel and scalable approach to personalized cancer treatment. Further research and clinical validation are needed to optimize their design, improve manufacturing efficiency, and assess their efficacy in human trials. CircRNA vaccines represent a next-- generation platform with the potential to revolutionize cancer immunotherapy by harnessing durable and targeted anti-tumor immune responses.

1 April 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
MHMd Sadique Hussain
Md Sadique Hussain
Mudasir MaqboolMudasir Maqbool
Mudasir Maqbool
Mohit AgrawalMohit Agrawal
Mohit Agrawal
ARAmita Joshi Rana
Amita Joshi Rana
ASAyesha Sultana
Ayesha Sultana
GKGyas Khan
Gyas Khan
Emerging evidence reveals that interactions between the nervous system and tumor biology significantly influence cancer progression, metastasis, and therapeutic outcomes. Here, we elucidate the neurobiological mechanisms that underpin tumor development, highlighting the dynamic role of neural components within the tumor microenvironment (TME). Neural signals and structural adaptations in the TME stimulate tumorigenesis and enable cancer cell plasticity, mimicking neurodevelopmental processes. Astrocytic glial cells release neurotrophic factors that support metastatic colonization and enhance tumor cell survival. Notably, cancer cells can establish pseudo-tripartite synapses with neurons, promoting both proliferation and invasion. We explore the cancer-neural network interplay, emphasizing how axonal remodeling, circuit reorganization, and synaptic dysfunction not only drive tumor growth but also contribute to associated symptoms like seizures and chronic pain. Molecularly, mutations such as in PIK3CA and abnormalities in neurotransmitter signaling reveal how neurotumors communicate and adapt. Furthermore, metabolic stress responses from tumor cells can activate nociceptive neurons, sustaining malignant progression. Understanding these neurobiological interactions opens avenues for novel therapeutic strategies. Precision neuro-oncology may benefit from targeting neurotrophic signaling, synaptic pathways, and neuronal differentiation programs. Advances in biomarker research from neurotumors also contribute to improved diagnostic and prognostic tools. By integrating neuroscience insights into oncological frameworks, we propose a paradigm shift toward therapies that intercept the neural circuitry sustaining malignancies. This neuro-oncological approach holds promise in addressing aggressive cancer phenotypes and improving patient outcomes.

16 September 2025 in Current Traditional Medicine
Verified
Journal Article
Closed access
MHMd Sadique Hussain
Md Sadique Hussain
VJVikas Jakhmola
Vikas Jakhmola
Mudasir MaqboolMudasir Maqbool
Mudasir Maqbool
ARAmita Joshi Rana
Amita Joshi Rana
ASAyesha Sultana
Ayesha Sultana
GGGaurav Gupta
Gaurav Gupta
Introduction: Laurus nobilis (bay laurel) is a widely used plant known for its culinary, cosmetic, therapeutic, and pharmacological properties. Its leaves are particularly valued due to their rich content of bioactive compounds, such as essential oils, phenolic substances, flavonoids, and alkaloids. This review aimed to provide a comprehensive overview of the botanical characteristics, chemical composition, and therapeutic and industrial applications of these compounds. Methods: An extensive literature review was conducted using scientific databases to collect and analyze published studies on the botanical traits, chemical constituents, traditional uses, pharmacological activities, and industrial applications of L. nobilis leaves. Results: The analysis revealed that bay leaves contain a variety of bioactive components, notably essential oils, phenolics, flavonoids, and alkaloids. These compounds exhibit significant pharmacological properties, including anti-inflammatory, antimicrobial, antioxidant, and anticancer activities, as supported by various in vitro and in vivo studies. Discussion: The findings underscore the therapeutic relevance of L. nobilis leaves, aligning with traditional medicinal practices and modern pharmacological research. However, limitations exist in terms of standardized extraction methods and clinical trials, which must be addressed to validate and optimize their therapeutic use. Conclusion: Laurus nobilis leaves are a promising natural source of pharmacologically active compounds. Their diverse applications across traditional medicine, modern pharmacology, and industrial sectors highlight their continuing relevance and potential for broader utilization.

1 March 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
ASAyesha Sultana
Ayesha Sultana
ASAbdul Rahman Shafeeh
Abdul Rahman Shafeeh
MAMohammed Gulzar Ahmed
Mohammed Gulzar Ahmed
ARAbdul Rahamanulla
Abdul Rahamanulla
GKGyas Khan
Gyas Khan
MHMd Sadique Hussain
Md Sadique Hussain
Crocus sativus (saffron) is a valuable medicinal plant with a rich phytochemical profile, including bioactive carotenoids, flavonoids, and terpenoids. The key constituents of saffron, crocin, crocetin, picrocrocin, and safranal, exhibit potent neuroprotective properties, with crocin, a water-soluble carotenoid, plays a crucial role in promoting neurogenesis and mitigating depressive symptoms. Depression, affecting approximately 280 million individuals globally (WHO, 2023), is closely associated with impaired neurogenesis, highlighting the need for novel treatment strategies. Crocus sativus, particularly in its nanotherapeutic form, shows promise in the treatment of depression by effectively crossing the blood-brain barrier and modulating neurotransmitter systems. In addition to its carotenoids, saffron contains flavonoids, such as kaempferol and quercetin derivatives, which contribute to its antioxidant and anti-inflammatory activities. This review explores the phytochemical composition of Crocus sativus, its role in neurogenesis, and its potential as a therapeutic agent for depression and neurodegenerative disorders.